AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DIACEUTICS PLC

Board/Management Information Dec 22, 2020

7596_rns_2020-12-22_dd27b9d9-98bd-4a0b-ba99-f9e17627eda4.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 4363J

Diaceutics PLC

22 December 2020

Diaceutics PLC

("Diaceutics" or the "Company")

Directorate change

Diaceutics PLC (AIM: DXRX), announces the appointment of Deborah Davis as Non-Executive Chair, effective from 4 January 2021. Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon. 

She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd (until 31/12/20). Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.

Peter Keeling, Chief Executive Officer of Diaceutics said: "I am delighted to attract someone of Deborah's relevant technology background and global experience to join our mission at Diaceutics. With the recent pivotal launch of our DXRX - Precision Testing Network platform, we have truly entered a new chapter in the Company's trajectory and I look forward to working with Deborah to capitalise on this."

Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Deborah Lee Davis (Llewelyn), aged 57, is currently or has previously been a director or partner of the following directorships or partnerships within the past five years:

Current directorships/partnerships Historic directorships/partnerships
IPF PLC IE DIGITAL (formerly Intelligent Environments Europe)
Institute of Directors
IDEX Biometrics ASA
WHICH? LTD
SA CONSERVATION TRUST

Save for the information disclosed above, there is no other information to be disclosed on Deborah Davis under Schedule 2(g) of the AIM Rules.

Deborah holds no shares in the Company.

Enquiries:

Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive Officer via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker) +44 (0) 20 7391 8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.  www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAKKDBNOBDDCBB

Talk to a Data Expert

Have a question? We'll get back to you promptly.